One prospective study of 555 patients reported that NT pro-BNP, mid-regional pro-atrial natriuretic peptide (MR-pro ANP), mid-regional proadrenomedulin (MR-proADM), C-terminal proendothelin-1 (CT-pro-ET-1), and hs-cTn T were elevated in an unselected population of patients with cancer prior to induction of any cardiotoxic anticancer therapy [25]. The gene discussed is NPPB; the disease is cancer.